Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer-associated fatigue is a prevalent and distressing symptom in patients receiving palliative chemotherapy. While short-term steroid use has been employed to alleviate fatigue, its long-term efficacy and safety remain unclear.
methodsThis phase III open-label, placebo-controlled randomized trial evaluated the efficacy and safety of dexamethasone (4 mg once daily for 12 weeks) versus placebo (once daily for 12 weeks) in patients with solid malignancies undergoing palliative chemotherapy. Fatigue was assessed using the Symbolic Assessment of Fatigue Extent (SAFE) and EORTC FA-12 scales, and quality of life (QOL) was measured using the EORTC QLQ-C30 at baseline, 6 weeks, and 12 weeks.
resultsFrom October 2018 to September 2022, 126 patients were randomized; 101 were evaluable (dexamethasone: 49, placebo: 52). The median age was 46.5 years, and 67% were female. Metastatic breast cancer (28%) and lung cancer (16%) were the most common diagnoses. There were no significant differences between the arms in mean SAFE scores at 6 or 12 weeks. At 12 weeks, patients in the placebo arm reported better role functioning on the FA-12 (P = 0.02). In the EORTC QLQ-C30, the dexamethasone arm had more constipation at 6 weeks (P = 0.03) and 12 weeks (P = 0.01), and greater social sequelae at 12 weeks (P = 0.048). No significant differences in adverse events were observed between the arms.
conclusionDexamethasone did not significantly reduce cancer-associated fatigue or improve QOL in patients receiving palliative chemotherapy. The findings highlight the need to explore alternative, more effective interventions for managing fatigue in this population.
trial registrationCTRI/2018/08/015222, date: 07/08/2018.
Indexed as
Identifiers
40739403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.